UK
Health analytics
US access solutions
At LCP US Access Solutions we deliver value-based, evidence-driven solutions through deep clinical insight and strategic consulting.
Our multidisciplinary team — including physicians and pharmacists — guides clients across three core pillars: market access (pricing, reimbursement, patient services and channel strategy), health economics and outcomes research (HEOR), and value and evidence generation.
We integrate advanced analytics, patient-focused innovation, and a commitment to ethical, sustainable practices to simplify complex market dynamics. By forming true partnerships with pharmaceutical and biotech companies, we help simplify the complex market dynamics and achieve excellence in outcomes for patients and the healthcare systems alike.
Why have we launched US access solutions?
Explore why LCP Health Analytics launched US access solutions, bringing integrated global expertise to pricing, access, and value consulting.
Through our suite of services we aim to simplify the complex US access landscape for pharmaceutical and biotech manufacturers
Our expertise across US market access strategy and implementation include:
Pricing and reimbursement
Pricing isn’t just about setting a number; it’s a critical lever for capturing the full value of a therapy. We take a comprehensive, data-driven approach to understanding the key drivers that influence pricing and reimbursement decisions. By rigorously testing and analyzing these factors, we empower companies to make informed, strategic pricing choices – across public and private channels – supporting market success and patient access.
Payer value and communication
As key decision-makers in determining access to medications, payers play a pivotal role in the healthcare ecosystem. Understanding how they define and perceive value is essential for shaping meaningful engagement. Our approach begins with a thorough assessment of payer perceptions of our clients’ products and identifies the core value drivers that resonate most. This insight forms the foundation for strategic, impactful communication — ultimately supporting optimal access for both caregivers and the patients they serve.
Patient services
In the ever-changing and complex world of healthcare, delivering exceptional patient care goes beyond treatment; it involves a holistic approach to support and engagement. We leverage our extensive expertise to develop tailored patient support programs that address the unique needs of your patient population. By building strategies and implementing programs with integrated comprehensive education, adherence strategies, and emotional support, we ensure patients are empowered throughout their healthcare journey. Our goal is to enhance patient outcomes and satisfaction, fostering a positive and supportive environment for all.
Trade and channel
In the pharmaceutical industry, effective trade and channel strategies are crucial for maximizing market reach and ensuring product availability. Our expertise lies in developing and implementing robust trade strategies that align with market dynamics and regulatory requirements. By leveraging data-driven insights and industry best practices, we help manufacturers optimize their distribution channels, enhance supply chain efficiency, and ensure timely delivery of therapies to patients. Our goal is to support manufacturers in achieving sustainable growth and market success.
As part of our integrated offer we provide the breadth of HEOR and real world evidence solutions to ensure access success.
Reach out to us today to learn more about how we can empower you to enhance value, improve access, and deliver better outcomes across the healthcare ecosystem
Let's talk
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Explore how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
Get in touch
Contact us to learn more about how we can provide clarity and insight in today’s increasingly complex life sciences and healthcare environment.
